Many stakeholders agree that the current business model for antibiotics is broken. Antibiotic innovation has slowed and many of the drugs on the market are losing effectiveness because of resistance. Professor Kevin Outterson is working at Chatham House on evaluating alternatives that will promote both innovation and long-term sustainability of this valuable resource.
Many stakeholders agree that the current business model for antibiotics is broken. Antibiotic innovation has slowed and many of the drugs on the market are losing effectiveness because of resistance. Professor Kevin Outterson is working at Chatham House on evaluating alternatives that will promote both innovation and long-term sustainability of this valuable resource.
A Professor of Law at Boston University, Professor Outterson is a Visiting Fellow at the Royal Institute of International Affairs at Chatham House. His research interests include global pharmaceutical markets, finance and organisation of health care systems, and antimicrobial resistance, particularly those threatened by the development of resistance. He leads an interdisciplinary project on the legal ecology of antimicrobial resistance, is a faculty affiliate at the Harvard Center for Communicable Disease Dynamics, and an appointed member of the Antimicrobial Resistance Working Group at the CDC.
Professor Outterson teaches health law and corporate law at Boston University, where he co-directs the Health Law Program. He serves as the editor-in-chief of the Journal of Law, Medicine & Ethics and is faculty co-advisor to the American Journal of Law & Medicine. Before teaching, Professor Outterson was a partner at two major US law firms.
The slide presentation for this seminar is available on OHE's SlideShare site: http://www.slideshare.net/OHENews/new-business-model-for-antibiotics-outterson-april-2014
